Kala Pharmaceuticals, Inc. is a leading developer of improved treatments for diseases that affect mucosal tissues. Using its proprietary mucus penetrating particle (MPP) technology platform, Kala is able to formulate active pharmaceutical ingredients so they are able to pass through human mucus secretions, in diverse organs, including the respiratory tract, eye, cervicovaginal tract and gastrointestinal tract. Kala's formulations result in a rapid, uniform distribution of drug-loaded particles in human mucus leading to enhanced local efficacy and reduced systemic exposure. The company is advancing its own internal pipeline while establishing research and development collaborations with select partners. Kala was co-founded by Colin Gardner (formerly of TransForm Pharmaceuticals/Johnson and Johnson, and Merck), Justin Hanes (Johns Hopkins University) and Robert Langer (MIT) and has an exclusive license to intellectual property from the laboratory of Dr. Hanes at the Johns Hopkins University School of Medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/14/12 | $6,200,000 | Seed |
Lux Capital Polaris Partners Third Rock Ventures | undisclosed |
| 02/28/13 | $11,500,000 | Series A |
Crown Venture Fund Lux Capital Polaris Partners Third Rock Ventures | undisclosed |
| 04/23/14 | $22,500,000 | Series B |
Crown Venture Fund Lux Capital Polaris Partners Third Rock Ventures Ysios Capital | undisclosed |
| 04/13/16 | $68,000,000 | Series C |
CAM Capital CVF Longitude Capital Lux Capital OrbiMed Advisors Polaris Partners RA Capital Vivo Ventures Wellington Management Company | undisclosed |
